Condition: Lazertinib · Sponsor: National Cancer Center, Korea
Using gefitinib or Osimertinib, an EGFR tyrosine kinase inhibitor (TKI), in patients with active mutations in epithelial cell growth factor receptors (EGFR), 70% response rate (CR+PR) and 90% disease control rate (CR+PR+SD) compared to the current non-small cell therapy, which is significant in the EFRT treatment. However, resistance causes recurrence in most patients. Therefore, it is necessary to develop a more effective treatment. Recently, in Japan, combined allotinib and bevacizumab therapy as primary therapy in non-small cell lung cancer patients with EGFR mutation improved PFS statistically significantly compared to allotinib monotherapy, suggesting the possibility of a new treatment (Hazard ratio 0.605, 95% CI 0.417-0.877, P=0.016). In addition, subsequent osmutinib and bevacizumab combination therapy showed a significant difference in PFS in the smoker group, although they did not show significant improvement in PFS in the entire patient group. (Hazard ratio 0.605, 95% CI 0.417-0.877, P=0.016). Since EGFR mutated lung cancer is highly frequent in Korea, it is necessary to develop more effective treatments for such patients. Therefore, we propose this clinical trial to find out the efficacy of lasertinib and bevacizumab combination therapy.
This description comes directly from the study's public registry record.
Beung-Chule AHN · +82-31-920-1676 · abcduke@ncc.re.kr
Always discuss trial participation with your own doctor first.
| The Catholic University of Korea, St. Vincent's Hospital | Suwon, Gyeonggi-do, South Korea | Not Yet Recruiting |
| National Cancer Center | Goyang-si, Gyeunggi-do, South Korea | Recruiting |
| AJOU university hospital | Suwon, Gyeunggi-do, South Korea | Not Yet Recruiting |
| Yonsei University Health System, Severance Hospital | Seoul, South Korea | Not Yet Recruiting |
| Gangnam Severance Hospita | Seoul, South Korea | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06156527